Rituximab for Aggressive Non-Hodgkin's Lymphoma (TA65)

Technology Appraisal Guidance No. 65

Source: National Institute for Health and Care Excellence

  • Rituximab is recommended for use in combination with a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for the first-line treatment of people with CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV (see Section 2.3). Rituximab is not recommended for use when CHOP is contraindicated.

  • The clinical and cost effectiveness of rituximab in patients with localised disease (Stage I, see Section 2.3) has not been established. It is recommended that rituximab be used in these circumstances only as part of ongoing or new clinical studies.

  • A specialist in the treatment of lymphomas should supervise the use of rituximab in combination with CHOP for the treatment of diffuse large-B-cell lymphoma.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://www.nice.org.uk/guidance/ta65

Copies of the document can also be obtained by contacting 0845 003 7783 or emailing publications@nice.org.uk and quoting reference number N0284.

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Rituximab for Aggressive Non-Hodgkin's Lymphoma.
Issue Date: September 2003
Review Date: August 2006

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in